BACK TO CONGRESSES

EHA 2024

Jun 13 - 16, 2024 | Madrid, Spain

The agents listed below are currently under investigation. Their safety and efficacy have not been established.

Poster
Oral ARV-393 is a BCL6 Degrading PROTAC® Efficacious as a Monotherapy in B-Cell Lymphoma Preclinical CDX and PDX Models

SM Gough et al.

VIEW MATERIAL